3 results
Approved WMOCompleted
- To determine the response based on Palmo-plantar Pustulosis Psoriasis Area and Severity Index (PPPASI) at the end of treatment (week 24), or at the latest assessment for patients who withdraw prematurely
Approved WMOPending
Objectives• To evaluate the clinical efficacy of guselkumab in fistulizing, perianal Crohn*s disease• To assess the overall safety of guselkumabPrimary EndpointThe primary endpoint of this study is the proportion of participants who achieve combined…
Approved WMOCompleted
Part 1: To evaluate the effects of BIIB033 versus placebo on disability improvement over 72 weeks.Part 2: evaluate long-term safety profile of BIIB033 as an add-on therapy in subjects with MS.